Annexon, Inc. (NASDAQ:ANNX) Receives Average Rating of “Hold” from Brokerages

Shares of Annexon, Inc. (NASDAQ:ANNX) have been assigned a consensus recommendation of “Hold” from the five ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $17.3333.

A number of equities analysts have issued reports on ANNX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Annexon in a research note on Wednesday, October 8th. Wells Fargo & Company upped their price objective on Annexon from $14.00 to $27.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th.

Insider Transactions at Annexon

In related news, Director Muneer A. Satter acquired 422,613 shares of Annexon stock in a transaction dated Friday, November 21st. The stock was acquired at an average cost of $4.28 per share, with a total value of $1,808,783.64. Following the purchase, the director directly owned 9,728,637 shares in the company, valued at $41,638,566.36. The trade was a 4.54% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jung Choi bought 33,000 shares of the business’s stock in a transaction dated Monday, December 1st. The shares were bought at an average cost of $4.19 per share, for a total transaction of $138,270.00. Following the completion of the transaction, the director directly owned 33,000 shares of the company’s stock, valued at $138,270. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 1,867,958 shares of company stock valued at $7,248,043 over the last three months. 12.67% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Annexon

A number of institutional investors have recently bought and sold shares of the stock. Matauro LLC purchased a new stake in Annexon during the second quarter valued at about $27,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Annexon during the second quarter valued at approximately $29,000. 49 Wealth Management LLC acquired a new stake in shares of Annexon during the second quarter valued at approximately $29,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Annexon in the 3rd quarter valued at approximately $31,000. Finally, Engineers Gate Manager LP acquired a new position in Annexon in the 2nd quarter worth approximately $32,000.

Annexon Stock Down 2.2%

ANNX stock opened at $4.80 on Wednesday. The company has a 50-day simple moving average of $3.66 and a 200 day simple moving average of $2.91. The company has a market capitalization of $574.22 million, a P/E ratio of -3.40 and a beta of 1.20. Annexon has a fifty-two week low of $1.28 and a fifty-two week high of $5.66.

Annexon (NASDAQ:ANNX) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.03). Equities analysts anticipate that Annexon will post -0.96 EPS for the current year.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.